Physician profile
Sara E Perisin
NPI 1427865492
$1,022.40
in general payments reported to CMS, 2019-2025
13 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $241.23 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $161.63 | 2025 | Wegovy, Ozempic |
| Pfizer INC. | $154.52 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $111.03 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.76 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $59.69 | 2025 | |
| Amgen INC. | $48.63 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $47.97 | 2025 | Lokelma, Wainua |
| Scpharmaceuticals INC. | $41.76 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.52 | 2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $24.64 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $17.37 | 2025 | Opsumit, Uptravi |
| Atricure, INC. | $16.65 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Perisin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.